Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines

MENLO PARK, Calif.: MENLO PARK, Calif., June 30, 2021 /PRNewswire/ -- Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, announced today that it has raised $73M in Series B financing. The oversubscribed round was led by Viking Global Investors and included participation from Sherpalo Ventures and Hillspire. The funds...

Click to view original post